Search

Displaying results 6461 - 6470 of 7674 in total
  1. Drug

    Chamaecyparis obtusa wood oil

    go.drugbank.com/drugs/DB14341
    Investigational

    It is not an approved drug.

    Products: Phytoncide Su
  2. Drug

    Rosa centifolia flower oil

    go.drugbank.com/drugs/DB14363
    Investigational

    It is not an approved drug.

  3. Drug

    Olaflur

    go.drugbank.com/drugs/DB13290
    Investigational

    Olaflur which is also referred to as elmex gel is an ingredient used in toothpaste which helps in the prevention of dental caries.

  4. Drug

    2-Hydroxyestradiol

    go.drugbank.com/drugs/DB07706
    Experimental

    2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol. It is also a positional isomer of estriol. [A31630]

  5. Drug

    CTB001

    go.drugbank.com/drugs/DB18316
    Investigational

    CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.[L48146]

  6. Drug

    Roledumab

    go.drugbank.com/drugs/DB16317
    Investigational

    Roledumab is under investigation in clinical trial NCT02287896 (Pharmacokinetics and Safety of Roledumab in Rhd-negative Pregnant Women Carrying an Rhd-positive Foetus).

    Synonyms: Immunoglobulin g1-kappa, anti-(homo sapiens rhd(rhesus blood group d antigen, rhd, cd240d)), homo sapiens monoclonal antibody
  7. Drug

    AL-034

    go.drugbank.com/drugs/DB17471
    Investigational

    AL-034 (TQ-A3334) is an oral toll-like receptor 7 agonist developed for the treatment of chronic hepatitis B (CHB) viral infection.

  8. Drug

    NY-ESO-1 peptide vaccine

    go.drugbank.com/drugs/DB17498
    Investigational

    NY-ESO-1 peptide vaccine is an investigational cancer immunotherapy. It contains a peptide derived from the cancer-testis antigen (NY-ESO-1).

  9. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical

  10. Drug

    WIN 55212-2

    go.drugbank.com/drugs/DB13950
    Experimental

    WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical

    Synonyms: (2,3-Dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate